Related Experiment Videos
Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics
1Department of Medicine, Yale University School of Medicine, West Haven, Connecticut.
Abstract:
Twenty-four type II (non-insulin-dependent) diabetic patients poorly controlled on maximum doses of first-generation oral hypoglycemic agents were switched to glyburide. There was a significant decrease in glycosylated hemoglobin, but the level was normalized in only four patients; there was no correlation with age, weight, or duration of diabetes. The best predictor for improvement was initial failure on tolbutamide, as opposed to the other first-generation drugs. Patients not controlled with 500 mg/day of chlorpropamide were less likely to benefit from glyburide therapy.
Insights
Glyburide significantly lowered glycosylated hemoglobin in type II diabetes patients poorly controlled on other oral agents. Previous failure with tolbutamide predicted better glyburide response, while high-dose chlorpropamide indicated less benefit.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type II diabetes (non-insulin-dependent) often requires multiple oral hypoglycemic agents for glycemic control.
- First-generation oral hypoglycemic agents may be insufficient for some patients.
- Assessing alternative therapeutic options is crucial for managing poorly controlled diabetes.
Purpose of the Study:
- To evaluate the efficacy of glyburide in type II diabetic patients inadequately controlled by maximal doses of first-generation oral hypoglycemic agents.
- To identify predictors of a positive response to glyburide therapy.
Main Methods:
- A cohort of 24 type II diabetic patients on maximum doses of first-generation oral hypoglycemic agents were switched to glyburide.
- Glycosylated hemoglobin levels were measured before and after the switch.
- Patient demographics (age, weight, diabetes duration) and prior medication history were analyzed.
Main Results:
- Glyburide treatment resulted in a significant reduction in glycosylated hemoglobin levels.
- Glycemic normalization was achieved in only four patients.
- Initial failure on tolbutamide was the strongest predictor of improvement.
- Patients previously uncontrolled on 500 mg/day of chlorpropamide showed a lesser likelihood of benefiting from glyburide.
Conclusions:
- Glyburide can improve glycemic control in a subset of type II diabetic patients failing first-generation agents.
- Predictive factors, such as prior drug response, can guide glyburide therapy selection.
- Further investigation into patient-specific responses to oral hypoglycemic agents is warranted.